Skip to main content

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

[widgetkit id="1" name="CC Event Nav"]

Evaluation of the PI3Kδ Inhibitor ME-401 in Patients with Relapsed/Refractory Follicular Lymphoma

Smart Start: Final Results of Rituximab, Lenalidomide, and Ibrutinib Lead-In Therapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory CLL

Conceptual Model of CLL

A Systematic Review of the Efficacy of Ibrutinib-Based Combination Therapy for Mantle-Cell Lymphoma

SYK Inhibition with Fostamatinib in Waldenström’s Macroglobulinemia

Ibrutinib Maintenance Following Induction for Untreated MCL: Initial Safety Report

Phase 1/2 Trial of Cirmtuzumab plus Ibrutinib: Planned Analysis of Phase 1 CLL Cohorts

The ZUMA-8 Phase 1/2 Multicenter Study Evaluating KTE-X19 in Patients with Relapsed/Refractory CLL

A Phase 2 Study Investigating Umbralisib Monotherapy in Patients with Relapsed/Refractory MZL

2
3
4
5
6
7
8

Page 5 of 25
Results 41 - 50 of 242